Cancer Stem Cells: Innovative Approach for Testable Alternatives against Therapy Resistant Cancer

Main Article Content

Nitin T. Telang

Abstract

Chemo-resistant cancer stem cells represent a sub-population of cancer initiating phenotype in primary cancer. These cells evolve in to a metastatic phenotype via activation of multiple cell signaling pathways for cancer cell survival and epithelial-mesenchymal transition. Reliable cancer stem cell models represent a valuable experimental approach for drug discovery platform to identify efficacious testable alternatives against therapy-resistant cancer. Present commentary provides a systematic discussion of relevant conceptual and technical aspects of cancer stem cell biology and its significance for therapeutic alternatives.      

Article Details

How to Cite
TELANG, Nitin T.. Cancer Stem Cells: Innovative Approach for Testable Alternatives against Therapy Resistant Cancer. Medical Research Archives, [S.l.], v. 10, n. 8, aug. 2022. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/2968>. Date accessed: 28 sep. 2022. doi: https://doi.org/10.18103/mra.v10i8.2968.
Section
Review Articles

References

1. American Cancer Society-Facts and Figures. Atlanta: American Cancer Society, 2021.
2. National Comprehensive Cancer Network. 2022. www.nccn.org.
3. Drost J, Van Jaarsveld RH, Ponsioen B, et al: Sequential cancer mutations in cultured human intestinal cells. Nature 2015, 521: 43-47.
4. Levine AJ, Jenkins NA, Copeland NG: The roles of initiating truncal mutations in human cancers: The order of mutations and tumor cell type matters. Cancer Cell 2019, 35: 10-15.
5. Ye L, Jia Y, Ji KE, et al: Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. Oncol. Lett. 2015, 10: 1240-1250.
6. Yang Z, Zhang Q, Yu L, et al: The signaling pathways and targets of traditional Chinese medicine and natural medicine in triple-negative breast cancer. J. Ethnopharmacol. 2021, 264:113249.
7. Telang N: Natural phytochemicals as testable therapeutic alternatives for HER-2-enriched breast cancer (Review).World Acad. Sci. J. 2020 2:19.
8. Telang NT: The divergent effects of ovarian steroid hormones in the MCF-7 model for Luminal A breast cancer: Mechanistic leads for therapy. Int. J. Mol. Sci. 2022, 23, 4800.
9. Telang N: Stem cell models for genetically predisposed colon cancer (Review). Oncol. Lett. 2020, 20: 138.
10. Telang N: Drug-resistant stem cells: Novel approach for colon cancer therapy. Int. J. Mol. Sci. 2022, 23, 2519.
11. Barker N: Adult intestinal stem cells: Critical drivers of epithelial homeostasis and regeneration. Nat. Rev. Mol. Cell. Biol. 2014, 15:19-33.
12. Soteriou D, Fuchs Y: A matter of life and death: Stem cell survival in tissue regeneration and tumor formation. Nat. Rev. Cancer 2018, 18: 187-201.
13. Lytle NK, Barber AG, Reya T: Stem cell fate in cancer growth, progression and therapy resistance. Nat. Rev. Cancer 2018, 18: 669-680.
14. Yaeger R, Solit DB: Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting. Clin. Cancer Res. 2020, 26:1538-1540.
15. Shibue T, Weinberg RA: EMT, CSCs, and drug resistance: The mechanistic link and clinical implications. Nat. Rev. Clin. Oncol. 2017, 14: 611-629.
16. Yang F, Zhang J, Yang H: OCT-2, SOX-2 and NANOG positive expression correlates with poor differentiation, advanced disease stages and worse overall survival in HER-2+ breast cancer patients. Onco Targets Ther. 2018, 11: 7873-7881.
17. Manogaran P, Umapathy D, Karthikeyan M, et al: Dietary phytochemicals as a potential source for targeting cancer stem cells. Cancer Investig. 2021, 39: 349-368.
18. Naujokat C, Mc Kee DI: The “Big Five” phytochemicals targeting cancer stem cells: Curcumin, EGCG, sulforaphane, resveratrol and genistein. Curr. Med. Chem. 2021, 28: 4321-4342.
19. Meerson A, Khatib S, Mahajna J: Natural products targeting cancer stem cells for augmenting cancer therapeutics. Int. J. Mol. Sci. 2021, 22: 13044.
20. Hong M, Tan H-Y, Li S, et al: Cancer stem cells: The potential targets of Chinese medicines and their active compounds. Int. J. Mol. Sci. 2016, 17, 893.
21. Bruna A, Rueda OM, Greenwood W, et al: A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds. Cell 2016, 167: 260-274. e22.
22. Sachs N, de Ligt J, Kopper O, et al: A living biobank of breast cancer organoids captures disease heterogeneity. Cell 2018, 172: 373-386, e10.
23. Drost J, Clevers H: Organoids in cancer research. Nat. Rev. Cancer 2018, 18: 407-418.
24. Pan B, Zhao D, Liu Y, et al: Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform. In Vitro Dev. Biol. Anim. 2021, 57: 510-518.